1. Home
  2. CAC vs EYPT Comparison

CAC vs EYPT Comparison

Compare CAC & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAC
  • EYPT
  • Stock Information
  • Founded
  • CAC 1875
  • EYPT 1987
  • Country
  • CAC United States
  • EYPT United States
  • Employees
  • CAC N/A
  • EYPT N/A
  • Industry
  • CAC Major Banks
  • EYPT Biotechnology: Laboratory Analytical Instruments
  • Sector
  • CAC Finance
  • EYPT Industrials
  • Exchange
  • CAC Nasdaq
  • EYPT Nasdaq
  • Market Cap
  • CAC N/A
  • EYPT 579.4M
  • IPO Year
  • CAC 1997
  • EYPT 2005
  • Fundamental
  • Price
  • CAC $43.34
  • EYPT $10.15
  • Analyst Decision
  • CAC Hold
  • EYPT Strong Buy
  • Analyst Count
  • CAC 3
  • EYPT 8
  • Target Price
  • CAC $47.33
  • EYPT $24.75
  • AVG Volume (30 Days)
  • CAC 56.5K
  • EYPT 784.9K
  • Earning Date
  • CAC 07-29-2025
  • EYPT 08-06-2025
  • Dividend Yield
  • CAC 3.88%
  • EYPT N/A
  • EPS Growth
  • CAC 2.54
  • EYPT N/A
  • EPS
  • CAC 3.09
  • EYPT N/A
  • Revenue
  • CAC $184,324,000.00
  • EYPT $56,042,000.00
  • Revenue This Year
  • CAC $40.83
  • EYPT N/A
  • Revenue Next Year
  • CAC $5.29
  • EYPT N/A
  • P/E Ratio
  • CAC $14.04
  • EYPT N/A
  • Revenue Growth
  • CAC 13.26
  • EYPT 12.04
  • 52 Week Low
  • CAC $31.79
  • EYPT $3.91
  • 52 Week High
  • CAC $50.07
  • EYPT $13.99
  • Technical
  • Relative Strength Index (RSI)
  • CAC 71.29
  • EYPT 62.47
  • Support Level
  • CAC $38.11
  • EYPT $8.96
  • Resistance Level
  • CAC $40.92
  • EYPT $10.20
  • Average True Range (ATR)
  • CAC 0.99
  • EYPT 0.76
  • MACD
  • CAC 0.44
  • EYPT -0.03
  • Stochastic Oscillator
  • CAC 99.26
  • EYPT 62.90

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

Share on Social Networks: